In the United States, most glycolic acid and azelaic acid serums marketed as cosmetics do not require FDA pre-market approval. The FDA regulates cosmetics under the Federal Food, Drug, and Cosmetic Act (FD&C Act), which does not require a company to register products, file formulas, or obtain approval before selling. However, 'cosmetic' has a precise legal meaning, and acid serums can easily cross the line into drug territory based on their marketing claims.
A product is classified as a drug — not a cosmetic — if it is intended to affect the structure or function of the body or to treat a disease. For glycolic acid serums, claims like 'clinically treats acne,' 'reduces acne lesions by 40%,' or 'treats hyperpigmentation caused by melasma' are drug claims. If your marketing — including your website, labeling, social posts, or any promotional material — contains such language, the FDA can classify your serum as an unapproved new drug, which is a serious enforcement risk.
Safe cosmetic positioning typically uses language like 'visibly reduces the appearance of uneven skin tone,' 'helps skin look smoother over time,' or 'exfoliates to reveal brighter-looking skin.' Your cosmetic chemist and a regulatory consultant can help you draw this line correctly during label review.
Concentration thresholds matter too. The Cosmetic Ingredient Review (CIR) has assessed AHAs including glycolic acid and concluded they are safe at concentrations up to 10% in rinse-off products and up to 10% in leave-on products at pH 3.5 or above, when the product contains adequate UV protection instructions or sun-sensitivity warnings. Formulas exceeding these parameters are not automatically illegal, but they attract more FDA scrutiny and may warrant additional safety testing.
Azelaic acid at cosmetic concentrations (typically 10% or under in a leave-on serum) is generally treated as a cosmetic ingredient in the US. At 15–20%, it is the concentration used in FDA-approved prescription products (Finacea, Azelex) for rosacea and acne — so a 20% leave-on serum sold OTC with drug claims would be a significant regulatory red flag.
The Modernization of Cosmetics Regulation Act (MoCRA), effective December 2023, adds new requirements: facility registration with the FDA, cosmetic product listing, and a Serious Adverse Event Reporting (SAER) obligation. These apply to almost all US cosmetic companies and are not optional regardless of company size.
For brands targeting the EU, the regulatory picture is stricter. Annex III of the EU Cosmetics Regulation (EC 1223/2009) restricts AHAs and requires a mandatory on-label warning: 'Contains AHA. Avoid sun exposure. Use sunscreens.' A Cosmetic Product Safety Report (CPSR) prepared by a qualified EU Safety Assessor is mandatory before market entry, and a Responsible Person (RP) established in the EU or UK must be named on the label.
If you are uncertain about classification, a one-hour call with a US cosmetic regulatory consultant typically costs $200–$500 and can save you from a much more expensive problem later.
Ingredients in this answer: Glycolic Acid · Azelaic Acid
Read the full guide on Private Label Azelaic & Glycolic Acid Serum Manufacturer Low MOQ →